INC Research formally launched the first Site Advocacy Group (SAG), initially focused on central nervous system (CNS) protocols.
INC Research formally launched the first Site Advocacy Group (SAG), initially focused on central nervous system (CNS) protocols. Since first announcing their expanded relationship with SCRS in December, INC has been working to create the SAG and officially launched it last week with a kickoff meeting at their Austin, Texas location, which serves as a primary hub for INC’s CNS clinical trials work.
A recent study by the Tufts Center for the Study of Drug Development found that drugs to treat CNS diseases, such as epilepsy, Alzheimer’s, autism, schizophrenia and depression, take 35 percent longer to develop than other drugs. Progress can be difficult to quantify with these diseases, making it even more critical for investigators and site staff to follow protocols consistently. Members of INC Research’s scientific and operational SAG specialize in psychiatry, with at least 10 years’ experience in schizophrenia, ADHD, depression and/or bipolar disorder, and have five years’ experience as a principal investigator. The group will be involved on an ongoing basis in reviewing protocols and providing feedback and solutions to enhance the conduct of psychiatry studies.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.